



[Home](#)[Media](#)[Careers](#)[History](#)[Language](#)[Corporate Information](#)[Our Businesses](#)[R&D](#)[Therapies](#)[Investor Information](#)[CSR](#)[Home](#) > [Our Businesses](#) > [Strategic Business Units](#) > [Respiratory](#)

Respiratory



Cipla has been at the forefront of innovation for inhalation therapy in India. The Company has played a leading role in educating the nation on inhalation therapy and over the coming years we will continue to work on topics such as patient awareness, acceptance, compliance and usage, physician training, medical camps and counselling. Strongly focused on access and affordability, Cipla Respiratory continued to strengthen its efforts through the “BreatheFree” patient awareness and education programs across markets, dedicated to making a difference to both patients and medical practitioners.



Over the last **40** years, the Company has been focused on bringing this innovation to markets across the globe. Today, Cipla Respiratory products are available in over **100** countries. Cipla offers the world's largest portfolio of inhalation products, with **27** molecules and combinations across a range of devices, to suit individual patient needs. The Company manufactures Metered Dose Inhalers (pMDIs), dry powder inhalers, nasal sprays, nebulisers and a range of inhaled accessory devices. The company has five manufacturing facilities dedicated to respiratory products and is currently the third largest manufacturer of pMDIs in the world.

This year Cipla Respiratory launched several inhalation products across European markets. In parallel, significant progress has been made on the development of critical new products for the U.S. and other priority markets. The

**PLAINTIFFS'
TRIAL EXHIBIT****PTX0380**

exhibitsticker.com

MEDA_APTX03503151

CIP2071

Argentum Pharmaceuticals LLC v. Cipla Ltd.

IPR2017-00807

team of world-class specialists continues to collaborate seamlessly across functions to drive Cipla Respiratory to new frontiers. Competition remains aggressive and we need to continue to maintain our agility to retain our leadership.

During the year under review, Cipla acquired 60% stake in Jay Precision Pharmaceuticals Private Limited. As Cipla aims to make a strong foray in overseas markets, de-risking the Respiratory devices supply through backward integration is key to fix the foundation. The deal provides in-house access to technical know-how of current and future device design, development and manufacturing.

Cipla now has end-to-end capability across respiratory care covering the value chain from API, formulation, device development and manufacturing to medical and patient education.

Highlights of Cipla's devices

Transparent Rotahaler¹ – The world's first transparent dry powder inhaler

Revolizer – Novel single-dose capsule dry powder inhaler

Multi-haler – Multi-dose dry powder inhaler

Autohaler² – First breath-actuated metered dose inhaler in India

Zerostat and Zerostat VT – Non-static spacers

Babymask and Infantmask – For delivery of inhaled medications to young children

Nasal sprays – A variety of nasal sprays for treatment of nasal allergy

The widest range of Dry Powder Inhaler devices

Our DPIs have been developed to ensure consistent dose delivery through patient-friendly devices – Rotacaps and Multi-halers comprising the actives and a high grade excipient.

The Rotahaler, launched in 1996, heralded the era of

patient-friendly inhalation therapy. Transparent, simple to use, and with consistency of dose, it has transformed the lives of millions of asthmatics.

The Revolizer is a new generation, patient-friendly dry powder inhaler, exclusively developed by Cipla. It is probably the easiest device to use. The patient simply opens the Revolizer, inserts the Rotacap, shuts the device and inhales. It provides accurate dosing, even at low inspiratory flow rates. A revolution in inhalation therapy indeed.

The Multi-haler is a multiple dose dry powder inhaler device with an inbuilt dose counter. It disperses individual pre-metered doses from a blister and needs just a single step for use. A simple action of sliding the mouthpiece cover punctures a blister to release the drug powder, which is then inhaled through the mouthpiece. It gives precise and consistent dosing.

Cipla will soon launch an innovative inhaler which will bring important benefits for physicians, patients and healthcare providers on managing Obstructive Airway Disease (OAD). The new inhaler is called Synchrobreathe which is a novel, breath-actuated inhaler (BAI) with a dose counter.

devices

CORPORATE INFORMATION

At a Glance
Board of Directors
Partnership
Code of Conduct
Quality

R & D

Leader in Drug
Delivery
Formulation
Development
API
Development
Regulatory

THERAPIES

Cardiovascular	Children's Health
Dermatology and Cosmetology	Diabetes
HIV/AIDS	Hepatitis

INVESTOR INFORMATION

Financial Results
Annual Report and
Chairman's Speech
Conference Call Transcripts
Shareholder Information
Unclaimed Dividend

Plants & Capacities	Platform Technology	Infectious Diseases & Critical Care	Malaria	QUICK LINKS www.act-c.in www.breathefree.com www.carebeyondcure.org www.ciplamed.com
OUR BUSINESSES	CSR	Neurosciences	Oncology	
Geographies	CSR Report	Ophthalmology	Osteoporosis	
Strategic Business Units	Palliative Care	Respiratory	Urology	
Cipla New Ventures		Women's Health	Devices	

[Privacy Policy](#)
[Disclaimer](#)
[Contact Us](#)
[Site Map](#)
[Caution Notice - "Recruitment Fraud"](#)

Site by  **MAGNON\TBWA**

© Copyright 2016 Cipla Inc. All rights reserved

